Tuberculosis: Recent Updates in Basic Research, Drug Discovery and Treatment - Volume II

Building on the success of "Tuberculosis: Recent Updates in Basic Research, Drug Discovery and Treatment", we are pleased to announce the launch of Volume II.

Tuberculosis (TB) continues to be one of the deadliest infectious diseases, ranking among the top ten worldwide according to the World Health Organisation (WHO). Despite progress in developing new anti-tubercular treatments and combinatorial therapies, significant challenges remain, particularly due to the severe side effects associated with these treatments.

The recent COVID-19 pandemic has further exacerbated the situation, causing major setbacks in global TB programs. These challenges necessitate a revaluation of the goals and milestones of the WHO's 'End TB Strategy' to ensure meaningful progress in combating this global epidemic.

This Research Topic aims to advance both clinical and basic research in TB treatment, disease management, and drug discovery, with a specific focus on understanding the metabolic remodelling of Mycobacterium tuberculosis in response to various drugs. By addressing these critical areas, we aim to make significant strides in the diagnosis, treatment, and control of TB worldwide. The goal is to uncover novel insights into the pathogen's biology and develop more effective therapeutic strategies, ultimately leading to improved management of TB.

To gather further insights within this scope, we welcome articles addressing, but not limited to, the following themes:

• Investigations of pathogenesis and determinants of TB
• Comprehensive investigations into treatment/drug discovery (and/or development) against pulmonary TB
• Advancements in vaccines and diagnostic methodologies for TB
• Innovative therapeutic approaches for patients with MDR/XDR TB
• Explorations into the molecular and genetic underpinnings of mycobacteria in the context of metabolic responses to various drugs/lead molecules